Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment

用于可卡因成瘾治疗的长效可卡因代谢酶

• 批准号: 8636423
• 负责人: CHANG-GUO ZHAN
• 金额: $ 109.77万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8636423
• 关键词: Animals; Antibodies; Behavior; Binding; Binding Sites; Biological; Biological Assay; Butyrylcholinesterase; Cardiovascular system; Clinical; Clinical Data; Clinical Trials; Cocaine; Cocaine Abuse; Cocaine Dependence; Computer Simulation; Data; Development; Dose; Drug Kinetics; Enzymes; FDA approved; Goals; Half-Life; Human; Hydrolase; IgG1; Immunoglobulin G; In Vitro; Investigation; Investigational Drugs; Lead; Legal patent; Macaca mulatta; Medical; Metabolism; Molecular; Neuraxis; Neurons; Pharmaceutical Preparations; Pharmacodynamics; Physiological; Plasma; Preclinical Testing; Preparation; Proteins; Public Health; Rattus; Schedule; Self Administration; Testing; Vaccines; addiction; base; cocaine overdose; design; immunogenicity; improved; in vitro Assay; in vitro activity; in vivo; large scale production; mutant; novel; novel therapeutics; public health relevance; response; small molecule; social; stable cell line; success; therapy development; treatment strategy

DESCRIPTION (provided by applicant): Cocaine abuse is a major medical and public health problem. There is still no FDA-approved anti-cocaine medication. Disastrous medical and social consequences of cocaine abuse have made the development of an anti-cocaine medication a high priority. Enhancing cocaine metabolism by administration of human butyrylcholinesterase (BChE) is recognized as an efficient treatment strategy for cocaine overdose and addiction. However, the catalytic efficiency (kcat/KM) of wild-type BChE against the naturally occurring (-)- cocaine is low (kcat = 4.1 min-1 and KM = 4.5 ¿M). Nevertheless, we have recently designed and discovered a set of BChE mutants, known as cocaine hydrolases (CocHs), with >1,000-fold improved catalytic efficiency against (-)-cocaine compared to wild-type BChE. In vivo evidences and clinical data for the first one of our discovered and patented CocHs have demonstrated that our discovered CocHs are promising candidates for development of an anti-cocaine medication. Our recently designed, discovered and patented CocHs are significantly more potent. Built on our success in rational design and discovery of the CocHs, the currently proposed investigation is focused on rational design, preparation, and preclinical testing of a novel type of long-lasting CocH entities, denoted as Fc-CocH, obtained from fusion of CocH with Fc portion of human antibody IgG1. The specific aims are: (1) to design new molecular entities of Fc-CocH that potentially have not only a high catalytic efficiency against (-)-cocaine, but also a long biologicl half-life; (2) to prepare and test the designed Fc-CocHs for their in vitro activities; (3) to characterize the in vivo potency, pharmacokinetics, and immunogenicity of Fc-CocHs in rats and rhesus monkeys; (4) to evaluate the actual effects of the promising Fc-CocHs (identified in Aim 3) on the physiological and behavior responses of animals to cocaine by performing cardiovascular assays and self-administration assays in rhesus monkeys. Accomplishment of this proposed investigation will result in the identification and development of the best possible Fc-CocH entity that has not only a high in vivo potency in blocking physiological effects of cocaine, but also a long biological half- life without immunogenicity. The long-lasting Fc-CocH entity optimized in this investigation is expected to be highly effective and safe as a novel exogenous enzyme suitable for cocaine addiction treatment in humans.

描述（由申请人提供）：可卡因滥用是一个主要的医疗和公共卫生问题。目前还没有FDA批准的抗可卡因药物。可卡因滥用造成的不利的医疗和社会后果使开发一种抗可卡因药物成为高度优先事项。通过给予人丁酰胆碱酯酶（BChE）来增强可卡因代谢被认为是治疗可卡因过量和成瘾的有效策略。然而，野生型BChE对天然存在的（-）-可卡因的催化效率（kcat/KM）较低（kcat = 4.1 min-1和KM = 4.5 μ M）。尽管如此，我们最近设计并发现了一组BChE突变体，称为可卡因水解酶（CocH），与野生型BChE相比，对（-）-可卡因的催化效率提高了1,000倍以上。我们发现的第一个获得专利的CoCh的体内证据和临床数据表明，我们发现的CoCh是开发抗可卡因药物的有希望的候选者。我们最近设计、发现和获得专利的CocH更有效。基于我们在CoCh的合理设计和发现方面的成功，目前提出的研究集中在一种新型长效药物的合理设计、制备和临床前测试上。 CocH实体，表示为Fc-CocH，由CocH与人抗体IgG 1的Fc部分融合获得。具体目标是：（1）设计不仅对（-）-可卡因具有高催化效率，而且具有长生物半衰期的新的Fc-CocH分子实体;（2）制备并测试所设计的Fc-CocH的体外活性;（3）表征Fc-CocH在大鼠和恒河猴中的体内效力、药代动力学和免疫原性;（4）通过在恒河猴中进行心血管测定和自我给药测定来评估有前景的Fc-CoCh（在目的3中鉴定）对动物对可卡因的生理和行为反应的实际作用。完成该提议的研究将导致鉴定和开发最佳可能的Fc-CocH实体，其不仅在阻断可卡因的生理作用方面具有高的体内效力，而且具有长的生物半衰期而没有免疫原性。在本研究中优化的长效Fc-CocH实体预期作为适用于人类可卡因成瘾治疗的新型外源性酶是高度有效和安全的。